Two Chinese companies have been locked in a bidding war to buy United States automaker Fisker Automotive Holdings, Inc. The overall prospects of the company are bleak (it is in bankruptcy after all) but whoever purchases the company will own the eighteen patents it developed. Outside of entry into US market, whoever buys Fisker will not have much else to work with.
Fisker had received hundreds of millions in federal dollars to develop hybrid cars. However, it has not produced a car since 2012. It owns a factory formerly owned by General Motors but has let it fall into disrepair. After the company failed to meet milestones established by the Energy Department the company stopped receiving payouts from the federal government. Fisker then declared bankruptcy the bankruptcy judge set a February 12th date for an auction of Fisker’s assets.
The company’s patent holdings are particularly valuable to anyone looking to enter the alternative-fuels market. These patents include drivetrain technology for electric cars, cover grille designs, and a fender vent. Fisker also has pending patents on aluminum subframing and solar technology in vehicles. Whichever company obtains these patents will be able to avoid years of research and development and be able to implement these inventions in new car models. Even if these new patents are never utilized by the buyer, they can still sure others who infringe on those patents are collect hefty damages.
As you can see, patent protection has the potential to be very lucrative for both businesses and individuals alike. If you have an interest in submitting a patent application for you or your business, you can contact Stone Law at 732-444-6303 or leave us a message on our website.
Recent Posts
- Call Off Chicken Little: The Sky is Not Falling for Skinny Labeling After GSK v. Teva
- CAFC Committee Recommends Another Year of Sanctions Against Newman
- Massie Tells House IP Subcommittee Witnesses He’s ‘Appalled’ By Proposals to Rein in ITC’s Patent Powers
- CAFC Invalidates Remaining Claim on Data Transmission Patent, Remands Substitute Claims for Collateral Estoppel Determination
- NIH Intramural Licensing Guidelines Hit the Wrong Note at the Wrong Time